Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>KPV (Lysine-Proline-Valine)
PreclinicalHealing / anti-inflammatory

KPV (Lysine-Proline-Valine)

A three-amino-acid peptide corresponding to the C-terminal sequence of alpha-MSH, studied in inflammatory models — particularly inflammatory bowel disease — and often discussed in gut-health contexts.

CompoundKPV (Lysine-Proline-Valine)
CategoryAnti-inflammatory tripeptide
ClassHealing and Anti-Inflammatory Peptides
Evidence tierPreclinical
WADA statusNot individually listed; verify current status if subject to testing
Sold on this siteNo — this is a reference database

Overview

This entry covers KPV (Lysine-Proline-Valine), a anti-inflammatory tripeptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

A three-amino-acid peptide corresponding to the C-terminal sequence of alpha-MSH, studied in inflammatory models — particularly inflammatory bowel disease — and often discussed in gut-health contexts.

Mechanism of Action

KPV appears to interact with inflammatory signaling pathways, and alpha-MSH-derived peptides have documented anti-inflammatory effects in immune cells. Oral and topical routes have both been examined in models.

Research and Evidence

Published work is dominated by cell-culture and animal models of colitis and skin inflammation. Small exploratory human studies exist, but no registrational-quality trials support therapeutic claims.

Evidence in context: the Healing and Anti-Inflammatory Peptides class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

No systematic human safety data are available; the compound is not an approved medicine in major jurisdictions.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of KPV (Lysine-Proline-Valine)?

KPV (Lysine-Proline-Valine) is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

Is KPV (Lysine-Proline-Valine) an approved medicine?

No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for KPV (Lysine-Proline-Valine)?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for KPV peptide studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement